Login
$DBVT
$10.27 -$0.75 (6.76%) Live

$DBVT 8-K SEC Filings

Filed On Filing
28 Oct 2026 8-K: Results of Operations and Financial Condition

Submitted the Biologics License Application to U.S. FDA for the VIASKIN® Peanut Patch in children aged 4-7 Years and requested Priority Review

30 Sep 2026 8-K: Other Events

DBV Technologies Announces Submission of Biologics License Application to U.S. FDA for the VIASKIN® Peanut Patch in Children Aged 4-7 Years

16 Jul 2026 8-K: Results of Operations and Financial Condition

Continued productive engagement with the FDA in support of the BLA for the VIASKIN® Peanut Patch in children aged 4 through 7 years, with submission of the BLA anticipated in the third quarter of 2026

29 Jun 2026 8-K: Other Events

DBV Technologies Provides BLA Submission Update for the VIASKIN® Peanut Patch in Children Aged 4 through 7 Years; Working Collaboratively with FDA to Optimize Review Process in Preparation for Filing

05 Jun 2026 8-K: Departure/Election of Directors or Officers; Compensation

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangement of Certain Officers.

03 Jun 2026 8-K: Amendments to Articles/Bylaws; Change in Fiscal Year; Submission of Matters to a Vote of Security Holders

The Company was incorporated in the form of a French Limited Company (Société Anonyme) with a Board of Directors.

05 May 2026 8-K: Departure/Election of Directors or Officers; Compensation

On April 30, 2026 the Board of Directors (the “Board”) of DBV Technologies S.A. (the “Company”), upon recommendation of the Compensation Committee (the “Committee”) of the Board, approved the DBV Technologies 2026 Performance Share Unit ...

30 Apr 2026 8-K: Results of Operations and Financial Condition

Reported cash and cash equivalents of $229 million as of March 31, 2026 —providing funding into the second quarter of 2027 following the full exercise of the ABSA Warrants and BS Warrants issued in its March 2025 private placement (“PIPE...

26 Mar 2026 8-K: Results of Operations and Financial Condition

Continued advancing the VIASKIN® Peanut Patch clinical development programs in peanut-allergic toddlers (1 through 3 years old) and children (4 through 7 years old)

02 Mar 2026 8-K: Other Events

Approximately 83% of children treated with the VIASKIN® Peanut Patch increased their eliciting dose at month 12, compared to approximately 48% in the placebo group

20 Jan 2026 8-K: Other Events

DBV Technologies Announces €166.7 Million in Gross Proceeds Following the Full Exercise of the ABSA Warrants and BS Warrants Issued on its March 2025 Financing

16 Dec 2025 8-K: Other Events

DBV Technologies Announces Positive Topline Results from Phase 3 VITESSE Trial of VIASKIN® Peanut Patch in Peanut Allergic Children Aged 4-7 Years

30 Oct 2025 8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure

DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Market: DBVT), (the “Company” or “DBV”), a clinical-stage biopharmaceutical company, today announced the provisional appointment of a new independent director, Dr. Philina Lee...

29 Oct 2025 8-K: Results of Operations and Financial Condition

DBV closes Q3 2025 with a cash and cash equivalents balance of $69.8 million, taking cash runway into the third quarter of 2026

18 Sep 2025 8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure

DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Market: DBVT), (the “Company” or “DBV”), a clinical-stage biopharmaceutical company, today announced the resignation of Daniel Soland, as a member of its Board of Directors (t...

05 Sep 2025 8-K: Other Events

DBV Technologies S.A., a société anonyme formed under the laws of France, having its registered office at 107 avenue de la République, 92320 Châtillon, France, and registered with the registre du commerce et des sociétés of Nanterre unde...

29 Jul 2025 8-K: Results of Operations and Financial Condition

DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT – CUSIP: 23306J309), a clinical-stage biopharmaceutical company, today reported financial results for the Second Quarter of 2025. The quarterly and half-yea...

25 Jun 2025 8-K: Other Events

DBV Technologies Announces First Subject Screened in COMFORT Toddlers Supplemental Safety Study in Peanut Allergic Toddlers 1 – 3 Years Old

11 Jun 2025 8-K: Departure/Election of Directors or Officers; Compensation; Amendments to Articles/Bylaws; Change in Fiscal Year +1 more

The Company was incorporated in the form of a French Limited Company (Société Anonyme) with a Board of Directors.

30 Apr 2025 8-K: Results of Operations and Financial Condition

DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT – CUSIP: 23306J309), a clinical-stage biopharmaceutical company, today reported financial results for the First Quarter of 2025. The quarterly and three mon...

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support